TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device. AW Technologies is currently in the process of medical device registration of the TrachFlush in Japan, with market launch targeted in fiscal 2024..

东京&纽约&德国迪塞尔多夫——（商业新闻短讯）——AW Technologies和朝日化成集团的核心运营公司朝日化成医疗已就AW Technologies的TrachFlush™设备在日本签订了独家经销协议。AW Technologies目前正在日本进行TrachFlush医疗器械注册，预计2024财年上市。。

Developed by AW Technologies based on an invention by an intensivist, the TrachFlush is a medical device to reduce the discomfort of ventilated patients while lightening the workload on healthcare professionals during tracheal suctioning. The TrachFlush supports airway secretion (phlegm) management with a unique cuff pressure control system, and has received the CE Mark in Europe in 2020 and FDA clearance in the United States in 2023.

TrachFlush由AW Technologies根据重症监护医生的发明开发，是一种医疗设备，可减少通气患者的不适感，同时减轻医护人员在气管抽吸过程中的工作量。TrachFlush通过独特的袖带压力控制系统支持气道分泌（痰）管理，并于2020年在欧洲获得CE标志，2023年在美国获得FDA批准。

In Japan, marketing and sale is to be performed by Asahi Kasei Medical..

在日本，营销和销售将由旭化成医疗进行。。

With the push of a button, the TrachFlush deflates the cuff and utilizes the ventilator air pressure during an inspiratory cycle, and re-inflates the cuff before the cycle completes.

按下按钮，TrachFlush会在吸气循环中为袖带放气并利用呼吸机空气压力，并在循环完成之前重新充气袖带。

Ken Shinomiya, President of Asahi Kasei Medical, stated, 'We are delighted to add the TrachFlush to our product lineup in the intensive care field, where we have strength in the area of blood purification. By leveraging our experience and know-how in blood purification, we believe that this will deliver diverse value, such as enhancing patients’ QOL and reducing the burden on healthcare workers.'.

旭化成医疗总裁KenShinomiya表示，“我们很高兴将TrachFlush加入到重症监护领域的产品阵容中，我们在血液净化领域拥有优势。通过利用我们在血液净化方面的经验和专有技术，我们相信这将带来多种价值，例如提高患者的生活质量，减轻医护人员的负担。”。

Adam Hansen, CEO of AW Technologies, commented, 'We are very pleased and excited to announce our partnership with Asahi Kasei Medical. This partnership is very important for AW Technologies, and Asahi Kasei Medical will play a very important role in our expansion of TrachFlush globally. We believe the TrachFlush will have a great impact in the ICU – not only by preventing ventilator-associated pneumonia, but also by non-invasively preventing the accumulation of secretion in the airways.'.

AW Technologies首席执行官亚当·汉森（AdamHansen）评论道：“我们非常高兴和激动地宣布与朝日Kasei Medical的合作关系。这种合作伙伴关系对于AW技术非常重要，朝日化成医疗将在我们全球扩张TrachFlush方面发挥非常重要的作用。我们相信TrachFlush将对ICU产生巨大影响-不仅可以预防呼吸机相关性肺炎，还可以无创地防止气道分泌物积聚。”。

About AW Technologies ApS

关于AW Technologies ApS

AW Technologies is a Danish medical device company, established in 2018, focused on developing disruptive and innovative airway management solutions for mechanically ventilated patients in the ICU, including TrachFlush. For further information, please visit www.trachflush.com and www.awtechnologies.dk..

AW Technologies是一家成立于2018年的丹麦医疗器械公司，专注于为ICU的机械通气患者（包括TrachFlush）开发破坏性和创新性的气道管理解决方案。有关更多信息，请访问www.trachflush.com和www.awtechnologies.dk。。

About Asahi Kasei and Asahi Kasei Medical

关于旭化成和旭化成医疗

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care.

旭化成集团为全世界人民的生活做出了贡献。自1922年成立氨和纤维素纤维业务以来，旭化成一直通过积极的业务组合转型来满足各个年龄段不断发展的需求。该公司在全球拥有48000多名员工，通过其材料、住房和医疗保健三个业务部门为世界挑战提供解决方案，为可持续社会做出了贡献。

Asahi Kasei Medical is a core operating company in the Health Care sector. Its blood purification business comprises devices and systems for dialysis and therapeutic apheresis, and its bioprocess business comprises equipment for the manufacture of biotherapeutics, biosafety testing services, and biologics CDMO operations.

旭化成医疗是医疗保健领域的核心运营公司。其血液净化业务包括用于透析和治疗性单采血液分离的设备和系统，其生物加工业务包括用于制造生物治疗剂、生物安全测试服务和生物制剂CDMO操作的设备。

For more information, visit www.asahi-kasei.com and www.asahi-kasei.co.jp/medical/en/..

有关更多信息，请访问www.asahi-kasei.com和www.asahi-kasei.co.jp/medical/en/。。